Noble Life Sciences (NLS)

Attachments

*Architects: Biotechnology_Biomarkers
*Architects: Contract Research Organizations (CRO), Clinical Trials, IRB, Life Science Regulatory & Compliance Information Systems Companies
*Industry: Maryland (Medical & Health Information Technology, Biomedical, Biopharmaceutical & Biotechnology Sectors)
*Industry: Rockville, Maryland
*Portfolio Companies & Awardees: TEDCO
2011: Maryland Biotech Center awards $1.8M in grants (2011)
Venture Capital: Angel, Seed & Incubator Series

2013: Noble Life Sciences wins $100,000 TEDCO grant (2013)
2021: Press Release: Noble Life Sciences announces its collaboration with George Mason University to access the National Center for Biodefense and Infectious Diseases BSL-3 facility
Biomarker Qualification
BlackRock BioCapital
NLS is a preclinical contract research organization (CRO) owned and operated by scientists with decades of experience in drug, vaccine, and medical device development.
NLS offers services in pharmacology, disease models, early safety assessments, toxicology, PCR, Flow Cytometry, in vivo imaging, and cell-based assays
Noble Life Sciences is led by Ken Carter, former CEO of Germantown-based Avalon Pharmaceuticals (2013)
Srujana Cherukuri, Chief Executive Officer at NLS (2021)
Sykesville, Maryland
The company provides integrated GLP and non-GLP preclinical services designed to accelerate development of vaccines and therapeutics in the areas of cancer and infectious diseases.